Phase II evaluation of topotecan and navelbine in patients with recurrent ovarian, fallopian tube or primary peritoneal cancer

Keyphrases

• Topotecan 100%
• Fallopian Tube 100%
• Primary Peritoneal Cancer 100%
• Navelbine 100%
• Platinum Resistance 66%
• Platinum Sensitivity 66%
• Response Rate 33%
• Performance Status 33%
• Neutropenia 33%
• Renal Function 33%
• Median Overall Survival 33%
• Median Progression-free Survival 33%
• Chemotherapy 33%
• Response to Therapy 33%
• Kaplan-Meier Method 33%
• Treatment Regimen 33%
• Epithelial Ovarian Cancer 33%
• Hematotoxicity 33%
• Chi-square 33%
• Student's T-test 33%
• Toxicity Profile 33%
• Primary Peritoneal 33%
• Hepatic Function 33%
• Efficacy Profile 33%
• Platinum Doublets 33%
• 25Mg 33%
• Treatment-free Interval 33%
• Non-platinum 33%
• Vinorelbine 33%
• Platinum-sensitive Disease 33%

Medicine and Dentistry

• Topotecan 100%
• Primary Peritoneal Cancer 100%
• Vinorelbine 100%
• Fallopian Tube 100%
• Neutropenia 33%
• Progression Free Survival 33%
• Overall Survival 33%
• Kidney Function 33%
• Kaplan Meier Method 33%
• Krukenberg Tumor 33%
• Student T Test 33%
• Liver Function 33%
• Diseases 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Topotecan 100%
• Peritoneum Cancer 100%
• Vinorelbine 100%
• Progression Free Survival 33%
• Neutropenia 33%
• Overall Survival 33%
• Chemotherapy 33%
• Ovary Carcinoma 33%
• Diseases 33%